Experience
Bausch & Lomb Incorporated et al
Slayback Pharma LLC et al
Representing Bausch & Lomb and Eye Therapies in a Hatch-Waxman patent infringement litigation including preliminary injunction proceedings concerning an ANDA for generic versions of over-the-counter Lumify® ocular drops.
Bausch & Lomb Incorporated et al v. Slayback Pharma LLC et al, 3:21-cv-16766, D.N.J., Judges Kirsch, Singh
Bausch Health Ireland Limited et al. v. Lupin Limited et al.
Bausch Health Ireland Limited et al.
Intellectual Ventures I LLC et al. v. Toyota Motor Corp. et al.
Toyota Motor Corp. et al.
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
Novartis Pharmaceuticals Corporation et al.
Eidos Display, LLC et al. v. AU Optronics Corporation et al.
HannStar Display Corporation and Hannspree North America, Inc.
Uniloc USA, Inc. et al. v. Motorola Mobility LLC et al.
Motorola Mobility LLC et al.
Blitzsafe Texas, LLC v. BMW et al.
BMW et al.
Horizon Pharma v. Dr. Reddy's Laboratories, et al.
Horizon Pharma
Innovative Display Techs. LLC v. Hyundai Motor Co.
Toyota Motor Corp.
Sol IP, LLC v. Qualcomm Inc. et al.
Sol IP, LLC
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.